An Old Drug for a New Indication: Repurposing Fenfluramine From an Anorexigen to an Antiepileptic Drug

By |2019-06-10T12:57:02-05:00June 7th, 2019|Categories: DSF Research Review|Tags: , |

New treatments can arrive along a variety of pathways, and this review article describes an example of using a known drug in a new way - in this case, the trail by which fenfluramine became a drug candidate for Dravet Syndrome. Fenfluramine was found to accelerate weight loss in the 1960's, and was approved [...]

Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: A review of its benefit-risk profile in a new patient population

By |2017-07-24T18:48:44-05:00July 24th, 2017|Categories: DSF Research Review|Tags: , , , |

(Schoonjans AS, et al. 2017). Fenfluramine is currently in a Phase 3 clinical trial for Dravet syndrome sponsored by Zogenix, Inc. While primarily used in the 1980s and 1990s for obesity, there were reports of it reducing seizures in the pediatric epilepsy population. It was withdrawn from the market in 1997 due to reports of [...]

Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in SCN1A mutant zebrafish

By |2017-06-24T03:51:07-05:00May 8th, 2017|Categories: DSF Research Review|Tags: , , , |

(Sourbron J et al. 2017). Fenfluramine (FA) is known to affect serotonin (5-HT) levels in the brain, but there are several different 5-HT receptor subtypes that may be involved in FA's mechanism of action. This study explored the anti-epileptic mechanisms of FA in SCN1Lab-mutant zebrafish by selectively targeting each of the receptors believed to be involved [...]

Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: A prospective study of a new cohort of patients

By |2016-11-17T21:48:33-05:00October 28th, 2016|Categories: DSF Research Review|Tags: |

(Schoonjans, 2016). Fenfluramine, a weight-loss medication that has been shown to affect serotonin levels and decrease seizures in a small group of patients with Dravet syndrome in Europe, is currently in US clinical trials. In this study, nine European patients enrolled in a prospective open label clinical study on fenfluramine. “Prospective” refers to the fact [...]